Compare Jones Lang LaSalle Inc (JLL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Moderna, Inc. — how do they compare? Jones Lang LaSalle Inc trades at $325.29 (market cap $15.12B), while Moderna, Inc. trades at $59.38 (market cap $23.60B). The key difference: Moderna, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| JLL | MRNA | |
|---|---|---|
Market Cap | $15.12B | $23.60B |
Sector | Real Estate | Health |
52-Week High | $358.66 | $81.80 |
52-Week Low | $253.48 | $22.36 |
Enterprise Value | $18.66B | $19.70B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
